Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression

American Journal of Pathology

Volumn 178, Issue 3, 2011, Pages 1350-1360

  Karni Schmidt, Orit ^a   Castillo Martin, Mireia ^a   HuaiShen, Tian ^a   Gladoun, Nataliya ^a   Domingo Domenech, Josep ^a   Sanchez Carbayo, Marta ^c   Li, Yingchun ^a   Lowe, Scott ^d   Prives, Carol ^a   Cordon Cardo, Carlos ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; ISOPROTEIN; PROTEIN P63; UROPLAKIN;

ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UROGENITAL TRACT CANCER; UROTHELIUM;

EID: 79952747169     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.11.061     Document Type: Article

References (39)

1. Augustin M, Bamberger C, Paul D, Schmale H: Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm Genome 1998, 9:899-902 (Pubitemid 28507203)
2. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S: Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998, 4:839-843 (Pubitemid 28331028)
3. Yang A, Kaghad M, Caput D, McKeon F: On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002, 18:90-95
4. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998, 2:305-316
5. Deyoung MP, Ellisen LW: p63 and p73 in human cancer: defining the network. Oncogene 2007, 26:5169-5183
6. Finlan LE, Hupp TR: p63: the phantom of the tumor suppressor. Cell Cycle 2007, 6:1062-1071
7. Dohn M, Zhang S, Chen X: p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001, 20:3193-3205 (Pubitemid 32553672)
8. Helton ES, Zhu J, Chen X: The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem 2006, 281:2533-2542 (Pubitemid 43845713)
9. Lane D, Levine A: p53 research: the past thirty years and the next thirty years, Cold Spring Harb Perspect Biol 2010, 2:a000893
10. Olivier M, Hollstein M, Hainaut P: TP53 mutations in human cancers: origins, consequences, and clinical use, Cold Spring Harb Perspect Biol 2010, 2:a001008
11. Vousden KH, Prives C: Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431
12. Guo X, Mills AA: p63, cellular senescence and tumor development. Cell Cycle 2007, 6:305-311
13. Moll UM, Slade N: p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004, 2:371-386 (Pubitemid 39031071)
14. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, Petherbridge KM, Roop DR, Bradley A, Mills AA: p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci U S A 2006, 103:8435-8440 (Pubitemid 43838473)
15. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T: Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005, 7:363-373 (Pubitemid 40544653)
16. McKeon F: p63 and the epithelial stem cell: more than status quo? Genes Dev 2004, 18:465-469
17. Senoo M, Pinto F, Crum CP, McKeon F: p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007, 129:523-536 (Pubitemid 46660965)
18. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR: p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004, 18:126-131 (Pubitemid 38141780)
19. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C: Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010, 28:401-408
20. Moll R, Divo M, Langbein L: The human keratins: biology and pathology. Histochem Cell Biol 2008, 129:705-733
21. Cheng W, Jacobs WB, Zhang JJ, Moro A, Park JH, Kushida M, Qiu W, Mills AA, Kim PC: DeltaNp63 plays an anti-apoptotic role in ventral bladder development. Development 2006, 133:4783-4792 (Pubitemid 46063090)
22. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, Ince TA, McKeon FD, Cordon-Cardo C: Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002, 161:1199-1206
23. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M: p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A 2005, 102:11355-11360 (Pubitemid 41153824)
24. Cordon-Cardo C: Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 2008, 218:154-165
25. Park BJ, Lee SJ, Kim JI, Lee CH, Chang SG, Park JH, Chi SG: Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000, 60:3370-3374 (Pubitemid 30482148)
26. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C: p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002, 8:494-501 (Pubitemid 34193969)
27. Comperat E, Bieche I, Dargere D, Ferlicot S, Laurendeau I, Benoit G, Vieillefond A, Verret C, Vidaud M, Capron F, Bedossa P, Paradis V: p63 gene expression study and early bladder carcinogenesis. Urology 2007, 70:459-462
28. Comperat E, Camparo P, Haus R, Chartier-Kastler E, Bart S, Delcourt A, Houlgatte A, Francois R, Capron F, Vieillefond A: Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma: a tissue microarray study of 158 cases. Virchows Arch 2006, 448:319-324 (Pubitemid 43361886)
29. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, Ando N, Takizawa T, Kageyama Y, Kihara K: Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003, 9:5501-5507 (Pubitemid 37499468)
30. Koga F, Kawakami S, Kumagai J, Takizawa T, Ando N, Arai G, Kageyama Y, Kihara K: Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer 2003, 88:740-747 (Pubitemid 36411454)
31. Fukushima H, Koga F, Kawakami S, Fujii Y, Yoshida S, Ratovitski E, Trink B, Kihara K: Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Res 2009, 69:9263-9270
32. He Y, Wu X, Tang W, Tian D, Luo C, Yin Z, Du H: Impaired delta NP63 expression is associated with poor tumor development in transitional cell carcinoma of the bladder. J Korean Med Sci 2008, 23:825-832
33. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D: AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 2000, 97:5462-5467 (Pubitemid 30313741)
34. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, Poliak N, Califano J, Trink B, Ratovitski E, Sidransky D: DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002, 1:369-379 (Pubitemid 41039138)
35. Taniere P, Martel-Planche G, Saurin JC, Lombard-Bohas C, Berger F, Scoazec JY, Hainaut P: TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. Br J Cancer 2001, 85:721-726 (Pubitemid 32929471)
36. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C: Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001, 158:1245-1251 (Pubitemid 32281288)
37. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994, 56:347-353
38. George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA, Cote RJ: p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007, 25:5352-5358 (Pubitemid 350232209)
39. Basturk O, Khanani F, Sarkar F, Levi E, Cheng JD, Adsay NV: DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod Pathol 2005, 18:1193-1198 (Pubitemid 43079918)